In this installment of LustgartenLIVE! doctors Avery Posey, Edwin Manuel and Howard Crawford discuss the importance of equity, accessibility and diversity in pancreatic cancer research. Join us June 15 as we lead the way to new milestones in pancreatic cancer research.

Lustgarten and the Salk Institute announced a new strategic partnership supported by a $5 million grant and focused on identifying and validating potential targets for new pancreatic cancer drugs.

Solving the unique complexities of pancreatic cancer requires complex thinking and diversity of thought, education,training, background and experience.   We are committed to prioritizing and promoting diversity and inclusion acrossthe organization, including staff, volunteer leadership and research portfolio.  ResearchA rich field of experience and perspectives working on the complex problems associated with pancreatic cancer increases the […]

 HonorHealth researchers developed a novel drug combination therapy for pancreatic cancer patients that has become part of the new National Comprehensive Cancer Network guidelines for the disease, the system shared with Becker’s.

Between 1995 and 2018, non-Hispanic White and Hispanic women in the United States experienced the greatest increases in early-onset pancreatic cancer (EOPC) incidence, according to study results published in Gastroenterology.

The FDA granted an orphan drug designation to QXL138AM, a first in class masked Immunocytokine (MIC), for the treatment of patients with pancreatic cancers, according to Nammi Therapeutics, Inc.